Format

Send to

Choose Destination
Cancer Med. 2019 Dec 10. doi: 10.1002/cam4.2728. [Epub ahead of print]

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.

Author information

1
University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
2
Eli Lilly and Company, Indianapolis, IN, USA.
3
Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
4
Division of Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
5
Simon Cancer Center Indiana University Medical Center, Indianapolis, IN, USA.
6
Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.
7
Division of Medical Oncology, Department of Internal Medicine, Siteman Cancer Center, St. Louis School of Medicine, St. Louis, MO, USA.
8
Eli Lilly and Company, Windlesham, Surrey, UK.

Abstract

BACKGROUND:

Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet-derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in combination with doxorubicin.

METHODS:

This open-label randomized phase 1 trial enrolled 49 patients ages 27 to 83 with metastatic or locally advanced soft tissue sarcoma (STS). Patients participated in 21-day treatment cycles (up to 8) until they met discontinuation criteria. In cycles 1 and 2, patients received olaratumab (15 mg/kg in Part A, 20 mg/kg in Part B) and doxorubicin (75 mg/m2 ). In cycles 3 through 8, patients continued combination treatment (15 mg/kg olaratumab + doxorubicin). Effect of olaratumab on PK of doxorubicin was determined in patients who received all doses in cycles 1 and 2.

RESULTS:

PK properties of doxorubicin administered alone or in combination with olaratumab (15 or 20 mg/kg) were similar for AUC(0-tlast ), AUC(0-∞), and Cmax . PK properties of olaratumab (15 or 20 mg/kg) were also similar when administered alone or in combination with doxorubicin. Three patients died (2 of disease progression and 1 of neutropenic enterocolitis). Fatigue and nausea (>75% of patients) were the most common treatment-emergent adverse events (TEAEs). Other common TEAEs included musculoskeletal pain, mucositis, constipation, and diarrhea.

CONCLUSIONS:

Olaratumab at 15 or 20 mg/kg before doxorubicin infusion had no clinically relevant effect on systemic exposure to doxorubicin compared with doxorubicin alone in patients with metastatic or locally advanced STS.

KEYWORDS:

doxorubicin; monoclonal antibody; olaratumab; pharmacokinetics; soft tissue sarcoma

PMID:
31821732
DOI:
10.1002/cam4.2728
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center